Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Completed · Not applicable · Has a placebo group
Conditions studied: Alzheimer's Disease
In brief
A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood pressure. Research with prazosin has shown that it may be effective in treating behavioral problems by reducing excess adrenalin effects in the brain.
Key facts
- Study ID
- NCT01126099
- Run by
- Seattle Institute for Biomedical and Clinical Research
- People needed
- 20
- Starts
- 2010-03-01
- Expected to finish
- 2014-03-01
- Last updated by the study team
- 2015-05-21
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- No age limit
- Probable or Possible Alzheimer's Disease
- Disruptive agitated behaviors at least twice a week (overly anxious or excited, making offensive comments.....)
- Stable medications for 2 weeks
- Must have a caregiver who spends 10 hours per week caring for the participant and agrees to participate in all evaluation sessions
You may not qualify if…
- Cardiovascular: unstable angina, recent myocardial infarction, preexisting hypotension (systolic BP less than 110) or orthostatic hypotension (≥20 mmHg drop in systolic BP following 2 minutes of standing posture)
- Any unstable medical condition
- Exclusionary medications: current treatment with prazosin, other alpha-1 blockers (trazodone, sildenafil, vardenafil or tadalafil)
- Psychoactive medications: subjects may be psychoactive medication-free or be partial responders (by subjective assessment of referring health care professional) to one psychoactive medication from any of the following classes: antipsychotics, anticonvulsants, mood stabilizers, antidepressants, benzodiazepines, or buspirone. Partial response is defined as some improvement in agitated behavior but persistence of agitated behaviors severe enough to cause patient distress and/or difficulty with caregiving. Although not formally rated, this improvement is equivalent to a Clinical Global Impression of Change rating of no more than minimal improvement (improvement is noticed by not enough to improve patient function or caregiver's practical management of the patient).
- Psychiatric/behavioral: lifetime schizophrenia; current delirium, mania, depression, or uncontrolled persistent distressing psychotic symptoms (hallucinations, delusions), substance abuse, panic disorder, or any behavior which poses an immediate danger to patient or others or which results in the patient being too uncooperative to meet the requirements of study participation.
Where it is running
- Veterans Affairs Puget Sound Health Care System — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.